医学
分子诊断学
诊断试验
胸腔积液
分子生物标志物
诊断生物标志物
诊断准确性
胸腔镜检查
液体活检
重症监护医学
癌症
病理
放射科
肿瘤科
内科学
生物信息学
急诊医学
生物
作者
Pathmanathan Sivakumaran,Vandana Relan,Belinda E. Clarke,Edwina Duhig,Ian A. Yang,Rayleen Bowman,Gary Lee,Kwun M. Fong
出处
期刊:Future Oncology
[Future Medicine]
日期:2011-06-01
卷期号:7 (6): 737-752
被引量:62
摘要
Malignant pleural effusions (MPEs) are a common and important cause of cancer-related mortality and morbidity. Prompt diagnosis using minimally invasive tests is important because the median survival after diagnosis is only 4-9 months. Pleural fluid cytology is pivotal to current MPE diagnostic algorithms but has limited sensitivity (30-60%). Consequently, many patients need to undergo invasive diagnostic tests such as thoracoscopic pleural biopsy. Recent genomic, transcriptomic, methylation and proteomic studies on cells within pleural effusions have identified novel molecular diagnostic biomarkers that demonstrate potential in complementing cytology in the diagnosis of MPEs. Several challenges will need to be addressed prior to the incorporation of these molecular tests into routine clinical diagnosis, including validation of molecular diagnostic markers in well-designed prospective, comparative and cost-effectiveness studies. Ultimately, minimally invasive diagnostic tests that can be performed quickly will enable clinicians to provide the most effective therapies for patients with MPEs in a timely fashion.
科研通智能强力驱动
Strongly Powered by AbleSci AI